Labetalolo S.A.L.F.

Labetalol, the active ingredient in Labetalolo S.A.L.F., is a beta blocker presented as an intravenous solution for parenteral use. It is employed to manage hypertension, including hypertensive emergencies, by reducing peripheral vascular resistance and cardiac output, providing rapid blood pressure control in adult patients who need immediate therapy.

GNH USA supplies Labetalolo S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, ensuring quality and regulatory compliance for critical care settings through reliable logistics and dedicated support teams.

Labetalolo S.A.L.F. acts on the cardiovascular system to lower elevated blood pressure.

- Hypertension: lowers systemic blood pressure by decreasing peripheral vascular resistance and cardiac output. - Hypertensive emergencies: provides rapid blood pressure reduction in acute, life‑threatening situations. - Angina pectoris: helps relieve chest pain by reducing myocardial oxygen demand through combined alpha‑ and beta‑blockade.

Labetalolo S.A.L.F. may cause a range of adverse reactions.

Common Side Effects: - Dizziness: feeling light‑headed or unsteady. - Fatigue: unusual tiredness or lack of energy. - Headache: mild to moderate head pain. - Nausea: upset stomach or urge to vomit. - Flushing: warmth and redness of the face or neck. - Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects: - Severe hypotension: dangerously low blood pressure requiring medical attention. - Bronchospasm: narrowing of the airways, especially in patients with asthma. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac block: impaired electrical conduction of the heart. - Arrhythmias: irregular heart rhythms that may be life‑threatening. - Stevens‑Johnson syndrome: severe skin reaction with blistering.

Before using Labetalolo S.A.L.F., consider the following precautions.

- Monitor blood pressure: avoid excessive drops that could cause dizziness or syncope. - Assess cardiac function: use cautiously in patients with heart failure or conduction disorders. - Check respiratory status: avoid in patients with active asthma or severe chronic obstructive pulmonary disease. - Review hepatic function: dose adjustment may be needed in liver impairment. - Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. - Store below 25°C: keep in original container, protect from light and moisture.

Labetalolo S.A.L.F. can interact with several medicines.

Major Interactions (Avoid): - Combined use with other antihypertensives (e.g., ACE inhibitors, diuretics) may cause severe hypotension. - Concomitant beta‑agonists (e.g., albuterol) may reduce bronchodilator effectiveness. - Co‑administration with calcium‑channel blockers (e.g., verapamil) may increase risk of bradycardia.

Moderate Interactions (Monitor Closely): - NSAIDs may blunt the antihypertensive effect of labetalol. - Clonidine may cause rebound hypertension if stopped abruptly while on labetalol. - Insulin or oral hypoglycemics may have altered glucose control when combined with labetalol.